



Afimmune
Trintech Building
South County Business Park
Leopardstown, Dublin 18
t +353 (1) 294 6380
info@afimmune.com
www.afimmune.com

EudraCT Number: 2020-002911-23

Study ID: DS102A-08-CV2

Study Title: A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study to Assess the Mechanism of Action and Safety of Orally Administered Epeleuton in Patients with Type 2 Diabetes and Diabetic Complications.

Date of early termination: 08 April 2022

Reason why study was early terminated: The early termination reflects a business decision by Afimmune Ltd. to stop the study and is not due to a safety concern. Seven patients have been screened, no patient has been randomised into the trial.

Consequently, no results are available for this trial.